ClinicalTrials.gg
TerminatedNCT04097301Updated Jan 19, 2022Results posted

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

A Phase 1/2 interventional study of MLM-CAR44.1 T-cells at day 0 Single intravenous infusion in Acute Myeloid Leukemia and Multiple Myeloma, sponsored by AGC Biologics S.p.A.. Terminated at 3 sites in 2 countries. Open to participants aged 1 Year to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-19.

Sponsored by AGC Biologics S.p.A. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Inability to close the study in a clinically relevant time frame

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
1 Year to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 229 studies in Leukemia, Myeloid, Acute with a site in Italy — 45 open to participants now, 68 under way, 16 of them phase 3. Leukemia, Myeloid, Acute · Italy.

Enrollment
193rd of 196
8 · median 120
Started
2019
with 19 others
Phase 1/2
41 of 229
6 open now
Registered
132nd of 229
by date

Among the 229 studies in Leukemia, Myeloid, Acute with a site in Italy, this one is the 193rd largest by enrollment of the 196 interventional ones that give a count, is one of 20 that started in 2019, is one of 41 in phase 1/2, and was the 132nd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

45 of the 229 studies in Leukemia, Myeloid, Acute with a site in Italy are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 229 studies in Leukemia, Myeloid, Acute with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).

Read the detailed description

The study is a seamless Phase I/IIa, open-label, multicenter clinical trial that combines Phase I dose escalation based on toxicity with Phase IIa dose expansion based on antitumor activity. Considering the "first in human" nature of this clinical study, the Bayesian Optimal Interval Design (BOIN) has been chosen to minimize any risks of exposure to the novel CD44v6 CAR T-cells during dose escalation. The study population is made up of patients with relapsed/refractory AML or MM expressing CD44v6.

The medicinal product under investigation (MLM-CAR44.1 T-cells) is patient specific as it is prepared starting from lymphocytes of the patient collected through lymphocyte apheresis. These autologous T-cells are expanded in vitro in large numbers and genetically modified to express the CAR CD44v6ΔNL gene and thus acquire antitumor functions. As a safety feature, the MLM-CAR44.1 T-cells are genetically modified to also express the HSV-TK Mut2 gene (suicide gene), which can be selectively activated in case of severe toxicity through the administration of ganciclovir (GCV), leading to the death of proliferating CAR T-cells.

The aim of this study is to assess the safety, antitumor activity and feasibility of CD44v6 CAR T cell immunotherapy in AML and MM.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Multiple Myeloma
04

Who can participate

Ages eligible
1 Year to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all the following inclusion criteria to be eligible for the study.

  1. Written before any study-related procedure.
  2. Adults and children:

    1. Adults 18 to 75 (65) years old with AML or MM.
    2. Children 1 to 17 years old with AML, only in Phase IIa.
  3. Confirmed diagnosis of AML or MM as follows:

    1. AML: Primary or secondary AML (any subtype except acute promyelocytic leukemia) according to World Health Organization (WHO) classification.
    2. MM with as defined by the International Myeloma Working Group (IMWG).
  4. Patients with relapse or disease:

    1. AML patients must be unlikely to benefit from cytotoxic chemotherapy as follows:

      • Leukemia refractory to at least 2 induction attempts.
      • Leukemia in relapse within 1 year following complete response (CR) after at least 2 induction attempts.
      • High-risk leukemia in adults according to 2017 European LeukemiaNet (ELN) in first relapse after a hypomethylating agent or a cycle containing cytarabine at a dose ≥ 1g/sqm a day (e.g. FLAG-IDA), except for FLT3-mutated AML.
      • High-risk leukemia in children as defined by the Italian Association of Pediatric Hematology and Oncology (AIEOP).
    2. Patients with MM must have a relapse or refractory disease after at least 4 different prior treatments in 3 treatment lines, or 4 treatments in 2 treatment lines in case of early relapsing patients (relapse in less than 1.5 years). Treatments include:

      • Proteasome inhibitor
      • High-dose alkylating agent if patients less than 70 years old
      • Immunomodulatory drug (IMID)
      • A monoclonal antibody (i.e. anti CD38 monoclonal antibody)
  5. Positive 4v6 expression on tumor cells by flow cytometry.
  6. (ECOG) performance status 0-2.
  7. of at least 12 weeks.
  8. Adequate organ function (hepatic, cardiac, pulmonary).
  9. Recovery from toxicities of clinical consequence attributed to previous chemotherapy to v5.0 Grade 1 (i.e., certain toxicities such as alopecia will not be considered in this category).
  10. Ability to comply with study procedures, including hospitalization and protocol-specified acquisition of blood and/or bone marrow specimens.
  11. Willing to be followed up long term, i.e. a 15-year follow up as required by health authorities for cell and gene therapy products.
  12. Women of must test negative for pregnancy at enrolment and during the study.

Exclusion criteria

Exclusion Criteria:

At screening: patients must meet none of the following exclusion criteria to be eligible for the study:

  1. History of or candidate for stem cell transplantation.
  2. Cardiovascular, pulmonary, renal, and hepatic functions that in the judgment of the investigator are insufficient for the patient to undergo CAR T-cell therapy.
  3. Any history of or suspected current disorders (apart from vitiligo, resolved childhood atopic dermatitis, Graves' disease clinically controlled).
  4. History of rheumatologic disorders requiring specific treatment at any time in the patient's medical history.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    MLM-CAR44.1 T-cells infusion

    PHASE I: i.v. single dose of MLM-CAR44.1 T-cells: 0.5 x 10E6/Kg or 1 x 10E6/Kg or 2 x10E6/Kg according to the BOIN design. PHASE IIa: i.v. single dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD). Phase I and IIa Pre-treatment: lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3

    Drug: MLM-CAR44.1 T-cells at day 0 Single intravenous infusion

Interventions

06

What researchers measure

Primary outcomes

  1. Phase I: Maximum Tolerated Dose (MTD) and the Recommended Phase IIa Dose of MLM-CAR44.1 T-cells in AML and MM

    MTD established through BOIN design and the dose-limiting toxicities (DLTs) occurring following CAR T-cell infusion.

    Time frame: Within 30 days following CAR T-cell infusion, assessed as day 0

  2. Phase I: Overall Safety of Treatment With MLM-CAR44.1 T-cells

    Safety will be evaluated by analyzing the type, frequency and severity of adverse events (AE) and by monitoring for systemic reactions (fever, tachycardia, nausea and vomiting, joint pain, skin rash). Overall, 3 study emergent serious adverse events (SAEs) were reported in patients treated with MLM-CAR44.1 T-cells.

    Time frame: For 30 days following CAR T-cell infusion, assessed as day 0.

  3. Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 3 Months Post-infusion

    The absence of replication competent retrovirus (RCR) in blood specimens: 3 months post-infusion will be monitored by DNA PCR for the Galv gene. RCR search was conducted centrally using a quantitative molecular test, (real time quantitative PCR, q-PCR analysis) determining the absence of RCR by DNA PCR for the Galv and gag-pol genes on genomic DNA from patient's peripheral blood lymphocytes. The objective of this q-PCR analysis is to exclude the presence of RCR originated by recombination with PG13 packaging cell sequences by detecting the Galv and gag-pol transcripts in the transduced cells. The absence of the Galv and gag-pol transcripts can exclude the presence of an RCR, while its presence is not sufficient to indicate the presence of an RCR, and in this case further analysis is required.

    Time frame: 3 months after infusion (assessed as day 0)

  4. Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 6 Months Post-infusion

    The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene. RCR search was conducted centrally using a quantitative molecular test, (real time quantitative PCR, q-PCR analysis) determining the absence of RCR by DNA PCR for the Galv and gag-pol genes on genomic DNA from patient's peripheral blood lymphocytes. The objective of this q-PCR analysis is to exclude the presence of RCR originated by recombination with PG13 packaging cell sequences by detecting the Galv and gag-pol transcripts in the transduced cells. The absence of the Galv and gag-pol transcripts can exclude the presence of an RCR, while its presence is not sufficient to indicate the presence of an RCR, and in this case further analysis is required

    Time frame: 6 months after infusion (assessed as day 0)

  5. Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 12 Months Post-infusion

    The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene.

    Time frame: 12 months after infusion (assessed as day 0)

  6. Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 24 Months Post-infusion

    The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene.

    Time frame: 24 months after infusion (assessed as day 0)

  7. Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in AML.

    The hematologic disease response will be classified according to ELN criteria.

    Time frame: 2 months after MLM-CAR44.1 T-cell infusion, assessed as day 0

  8. Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in MM

    The hematologic disease response will be classified according to IMWG criteria

    Time frame: 3 months after T-cell infusion, assessed as day 0

Secondary outcomes

  1. Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in AML

    The hematologic disease response will be classified with the following response criteria: complete response (CR), incomplete response (CRi) and partial response (PR) according to ELN criteria.

    Time frame: 1 and 2 months following T-cell infusion, assessed as day 0

  2. Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in MM

    Hematologic disease response evaluated at Day 28 following CART-cell infusion, as overall response rate (ORR), stringent complete response (sCR), CR, very good partial response (VGPR) and partial response (PR).

    Time frame: 1 and 3 months following T-cell infusion, assessed as day 0

  3. Phase I: The Levels of Circulating MLM-CAR44.1 T-cells in Blood Samples

    The levels will be evaluated by flow cytometry and qPCR (in vivo pharmacokinetic profile).

    Time frame: At day 7, 14, 21, 28, 60, 90, 180 from infusion, assessed as day 0

  4. Phase I: The Percentage of Patients for Whom Activation of Suicide Gene Was Needed

    Suicide gene activation and elimination of transduced cells will be established through administration of ganciclovir in case of cytokine-release syndrome (CRS) and other MLM-CAR44.1 T-cell related toxicities.

    Time frame: At day 7, 14, 21, 28, 60, 90, 180 from infusion, assessed as day 0

  5. Phase IIa: Hematologic Disease Response in AML

    The hematologic disease response will be classified with the following response criteria: complete response (CR), incomplete response (CRi) and partial response (PR) according to ELN criteria.

    Time frame: 1, 2 and 6 months after MLM-CAR44.1 T-cell infusion, assessed as day 0.

  6. Phase IIa: Hematologic Disease Response in MM

    The hematologic disease response will be defined based on the overall response rate (ORR): stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to IMWG criteria

    Time frame: 1, 2 and 6 months after T-cell infusion, assessed as day 0

  7. Phase IIa: Overall Survival (OS)

    Overall Survival (OS) is defined as the time from the date of MLM-CAR44.1 T-cell infusion to the date of last follow-up or death due to any cause, whichever occurs first. One patients out of the 2 treated was still alive at the date of the early study termination. One patient died after EURE-CART-1 cell infusion, at day 121, for disease progression.

    Time frame: At the date of the early study termination

Other outcomes

  1. Exploratory Outcome of Phase IIa: Percentages of Patients With Minimal Residual Disease

    AML: proportion of patients with a molecular complete response (CR); MM: proportion of patients with a molecular CR.

    Time frame: AML: 2 months after infusion, assessed as day 0. MM: 3 months after infusion, assessed as day 0

07

Results

Posted Jan 19, 2022
Limitations and caveats
The early termination of this study is due to the analysis of its feasibility, based on the low patient recruitment rate (due to the lower-than-expected proportion of myeloma and leukemia expressing the CD44v6). A further decrease in the recruitment occurred with the diffusion of the COVID-19 emergency and the availability of new drugs for the treatment of myeloma and leukemia. These reasons make impossible to foresee the conclusion of the study in a clinically relevant time frame.

Participant flow

The study population originally planned is made up of: Adult patients 18 to 75 years old or 18 to 63 years old for CZ site, with relapsed/refractory AML or MM expressing CD44v6; Children 1 to 17 years old with AML, only in Phase IIa, except for CZ site. Up to the early termination of the study only adult patients 18 to 75 years old or 18 to 63 years old for CZ site, with relapsed/refractory MM expressing CD44v6 were recruited

Participant flow — Overall Study
MilestoneMLM-CAR44.1 T-cells Infusion
Started8
Treated patients2
Completed1
Not completed7
Withdrew: Death1
Withdrew: Withdrawal by subject1
Withdrew: Screening failure5

Outcome measures

PrimaryPhase I: Maximum Tolerated Dose (MTD) and the Recommended Phase IIa Dose of MLM-CAR44.1 T-cells in AML and MM

MTD established through BOIN design and the dose-limiting toxicities (DLTs) occurring following CAR T-cell infusion.

Time frame:
Within 30 days following CAR T-cell infusion, assessed as day 0

No measurements were reported for this outcome.

PrimaryPhase I: Overall Safety of Treatment With MLM-CAR44.1 T-cells

Safety will be evaluated by analyzing the type, frequency and severity of adverse events (AE) and by monitoring for systemic reactions (fever, tachycardia, nausea and vomiting, joint pain, skin rash). Overall, 3 study emergent serious adverse events (SAEs) were reported in patients treated with MLM-CAR44.1 T-cells.

Time frame:
For 30 days following CAR T-cell infusion, assessed as day 0.
Reported as:
Number · Number of SAEs
Phase I: Overall Safety of Treatment With MLM-CAR44.1 T-cells
Number of SAEsMLM-CAR44.1 T-cells Infusion
Phase I: Overall Safety of Treatment With MLM-CAR44.1 T-cells3
PrimaryPhase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 3 Months Post-infusion

The absence of replication competent retrovirus (RCR) in blood specimens: 3 months post-infusion will be monitored by DNA PCR for the Galv gene. RCR search was conducted centrally using a quantitative molecular test, (real time quantitative PCR, q-PCR analysis) determining the absence of RCR by DNA PCR for the Galv and gag-pol genes on genomic DNA from patient's peripheral blood lymphocytes. The objective of this q-PCR analysis is to exclude the presence of RCR originated by recombination with PG13 packaging cell sequences by detecting the Galv and gag-pol transcripts in the transduced cells. The absence of the Galv and gag-pol transcripts can exclude the presence of an RCR, while its presence is not sufficient to indicate the presence of an RCR, and in this case further analysis is required.

Time frame:
3 months after infusion (assessed as day 0)
Reported as:
Count of participants · Participants
Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 3 Months Post-infusion
ParticipantsMLM-CAR44.1 T-cells Infusion
Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 3 Months Post-infusion2
PrimaryPhase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 6 Months Post-infusion

The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene. RCR search was conducted centrally using a quantitative molecular test, (real time quantitative PCR, q-PCR analysis) determining the absence of RCR by DNA PCR for the Galv and gag-pol genes on genomic DNA from patient's peripheral blood lymphocytes. The objective of this q-PCR analysis is to exclude the presence of RCR originated by recombination with PG13 packaging cell sequences by detecting the Galv and gag-pol transcripts in the transduced cells. The absence of the Galv and gag-pol transcripts can exclude the presence of an RCR, while its presence is not sufficient to indicate the presence of an RCR, and in this case further analysis is required

Time frame:
6 months after infusion (assessed as day 0)
Reported as:
Count of participants · Participants
Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 6 Months Post-infusion
ParticipantsMLM-CAR44.1 T-cells Infusion
Phase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 6 Months Post-infusion2
PrimaryPhase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 12 Months Post-infusion

The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene.

Time frame:
12 months after infusion (assessed as day 0)

No measurements were reported for this outcome.

PrimaryPhase I: Absence of Replication Competent Retrovirus (RCR) in Blood Specimens: 24 Months Post-infusion

The absence of replication competent retrovirus (RCR) in blood specimens will be monitored by DNA PCR for the Galv gene.

Time frame:
24 months after infusion (assessed as day 0)

No measurements were reported for this outcome.

PrimaryPhase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in AML.

The hematologic disease response will be classified according to ELN criteria.

Time frame:
2 months after MLM-CAR44.1 T-cell infusion, assessed as day 0

No measurements were reported for this outcome.

PrimaryPhase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in MM

The hematologic disease response will be classified according to IMWG criteria

Time frame:
3 months after T-cell infusion, assessed as day 0
Reported as:
Count of participants · Participants
Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in MM
ParticipantsMLM-CAR44.1 T-cells Infusion
Phase IIa: Hematological Disease Response to MLM-CAR44.1 T-cells in MM0
SecondaryPhase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in AML

The hematologic disease response will be classified with the following response criteria: complete response (CR), incomplete response (CRi) and partial response (PR) according to ELN criteria.

Time frame:
1 and 2 months following T-cell infusion, assessed as day 0

No measurements were reported for this outcome.

SecondaryPhase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in MM

Hematologic disease response evaluated at Day 28 following CART-cell infusion, as overall response rate (ORR), stringent complete response (sCR), CR, very good partial response (VGPR) and partial response (PR).

Time frame:
1 and 3 months following T-cell infusion, assessed as day 0
Reported as:
Count of participants · Participants
Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in MM
ParticipantsMLM-CAR44.1 T-cells Infusion
No response detected2
Hematologic disease response0
SecondaryPhase I: The Levels of Circulating MLM-CAR44.1 T-cells in Blood Samples

The levels will be evaluated by flow cytometry and qPCR (in vivo pharmacokinetic profile).

Time frame:
At day 7, 14, 21, 28, 60, 90, 180 from infusion, assessed as day 0
Reported as:
Count of participants · Participants
Phase I: The Levels of Circulating MLM-CAR44.1 T-cells in Blood Samples
ParticipantsMLM-CAR44.1 T-cells Infusion
Positive at day 14 and 211
Negative at all monitoring time points1
SecondaryPhase I: The Percentage of Patients for Whom Activation of Suicide Gene Was Needed

Suicide gene activation and elimination of transduced cells will be established through administration of ganciclovir in case of cytokine-release syndrome (CRS) and other MLM-CAR44.1 T-cell related toxicities.

Time frame:
At day 7, 14, 21, 28, 60, 90, 180 from infusion, assessed as day 0

No measurements were reported for this outcome.

SecondaryPhase IIa: Hematologic Disease Response in AML

The hematologic disease response will be classified with the following response criteria: complete response (CR), incomplete response (CRi) and partial response (PR) according to ELN criteria.

Time frame:
1, 2 and 6 months after MLM-CAR44.1 T-cell infusion, assessed as day 0.

No measurements were reported for this outcome.

SecondaryPhase IIa: Hematologic Disease Response in MM

The hematologic disease response will be defined based on the overall response rate (ORR): stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to IMWG criteria

Time frame:
1, 2 and 6 months after T-cell infusion, assessed as day 0

No measurements were reported for this outcome.

SecondaryPhase IIa: Overall Survival (OS)

Overall Survival (OS) is defined as the time from the date of MLM-CAR44.1 T-cell infusion to the date of last follow-up or death due to any cause, whichever occurs first. One patients out of the 2 treated was still alive at the date of the early study termination. One patient died after EURE-CART-1 cell infusion, at day 121, for disease progression.

Time frame:
At the date of the early study termination

No measurements were reported for this outcome.

Other pre-specifiedExploratory Outcome of Phase IIa: Percentages of Patients With Minimal Residual Disease

AML: proportion of patients with a molecular complete response (CR); MM: proportion of patients with a molecular CR.

Time frame:
AML: 2 months after infusion, assessed as day 0. MM: 3 months after infusion, assessed as day 0

No measurements were reported for this outcome.

Adverse events

Collected over 15 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MLM-CAR44.1 T-cells Infusion1/2 (50%)2/2 (100%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventMLM-CAR44.1 T-cells Infusion
PneumoniaInfections and infestations2/2
Disease progressionGeneral disorders1/2
Most frequent other events
Most frequent other events
EventMLM-CAR44.1 T-cells Infusion
PyrexiaImmune system disorders2/2
NeutropeniaBlood and lymphatic system disorders2/2
AnemiaBlood and lymphatic system disorders2/2

Baseline characteristics

Overall, 8 patients were enrolled in the study and underwent the screening phase to evaluate the compliance to the clinical inclusion / exclusion criteria as well as the CD44v6 expression by tumor cells (Table 10). Of the 8 enrolled patients, 2 were treated with MLM-CAR44.1 T-cell at the first dose level. Five patients were screening failures and 1 patient dropped-out before lymphocyte apheresis for fulminant disease progression.

Age, Categorical
Age, Categorical(Participants)MLM-CAR44.1 T-cells Infusion
<=18 years0
Between 18 and 65 years7
>=65 years1
Age, Continuous
Age, Continuous(years)MLM-CAR44.1 T-cells Infusion
Median56 (41 to 66)
Sex: Female, Male
Sex: Female, Male(Participants)MLM-CAR44.1 T-cells Infusion
Female2
Male6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MLM-CAR44.1 T-cells Infusion
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White8
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)MLM-CAR44.1 T-cells Infusion
Italy5
Czechia3
Confirmed diagnosis of MM
Confirmed diagnosis of MM(Participants)MLM-CAR44.1 T-cells Infusion
Count of participants8
Patients with relapse or refractory disease
Patients with relapse or refractory disease(Participants)MLM-CAR44.1 T-cells Infusion
Count of participants8
08

Study locations

3 sites
  • Department of Haematooncology, Fakultni Nemocnice
    Ostrava, Czech Republic, Czechia
  • IRCCS San Raffaele
    Milan, Italy
  • IRCCS Ospedale Pediatrico Bambino Gesù
    Roma, Italy
09

References and documents

Publications

  • Stornaiuolo A, Valentinis B, Sirini C, Scavullo C, Asperti C, Zhou D, Martinez De La Torre Y, Corna S, Casucci M, Porcellini S, Traversari C. Characterization and Functional Analysis of CD44v6.CAR T Cells Endowed with a New Low-Affinity Nerve Growth Factor Receptor-Based Spacer. Hum Gene Ther. 2021 Jul;32(13-14):744-760. doi: 10.1089/hum.2020.216. Epub 2021 May 5. PubMed 33554732 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Jun 2021, 21 months.

Results were first posted in Jan 2022, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2019
First posted
Sep 20, 2019
StartActual
Aug 27, 2019
Primary completionActual
Jun 18, 2021
CompletionActual
Jun 18, 2021
Results first posted
Jan 19, 2022
Last update
Jan 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04097301
Lead sponsor
AGC Biologics S.p.A.
Collaborators
Horizon 2020 - European Commission
Responsible party
Sponsor
First posted
Sep 20, 2019
Start date
Aug 27, 2019
Primary completion
Jun 18, 2021
Completion
Jun 18, 2021
Results posted
Jan 19, 2022
Last update
Jan 19, 2022

Study contacts

Fabio Ciceri, MD
principal investigator · IRCCS San Raffaele

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chimeric Antigen Receptor T-cells

Start the discussion